Teclistamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more therapies [ID6201]
Awaiting development
Reference number: GID-TA11162
Expected publication date:
Please note that following on from an update received from the company, the appraisal has been scheduled back into the work programme. The appraisal is now anticipated to begin during late September 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately late November 2024.